The efficiency of Ramucirumab therapy for advanced gastric cancer after chemotherapy

The efficiency of Ramucirumab therapy for advanced gastric cancer after chemotherapy - Ramuciru-AC

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021330

Enrollment

Registered

2016-06-01

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Try Ramucirumab monotherapy for gastric cancer. Over a period of 60 minutes once Ramucirumab 8mg / kg for intravenous infusion every two weeks. Administration of Ramucirumab will continue until wors

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who were received all kind of chemotherapy as much as possible

Exclusion criteria

Exclusion criteria: serious underlying disease

Design outcomes

Primary

Measure	Time frame
PSF,RR,OS	—

Countries

Japan

Contacts

Public ContactTomoyuki Shibata

Fujita Health University Gastroenterology

tshibata-04@umin.ac.jp+81-562-93-9240

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026